Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• Cyclin-dependent kinase 2 (CDK2) is a key regulator of the cell cycle.
• Hyperactivation of CDK2 is observed in various cancers, making it a significant therapeutic target.
• Understanding CDK2's role and compensatory mechanisms is crucial for developing effective cancer treatments.

Purpose of the Study:

• To investigate CDK2 substrate phosphorylation, cell-cycle progression, and drug adaptation in response to CDK2 inhibitors.
• To explore the compensatory roles of other cyclin-dependent kinases (CDKs) during CDK2 inhibition.
• To determine the potential for combined CDK2 and CDK4/6 inhibition to overcome drug resistance.

Main Methods:

• Utilized preclinical models with several CDK2 inhibitors in clinical development.
• Assessed CDK2 substrate phosphorylation and cell-cycle progression upon CDK2 inhibition.
• Investigated the impact of CDK4/6 activity on CDK2 inhibitor efficacy and cellular adaptation.

Main Results:

• Acute CDK2 inhibition led to rapid loss of substrate phosphorylation, which rebounded within hours.
• CDK4/6 activity compensated for CDK2 inhibition by maintaining Rb1 hyperphosphorylation and E2F transcription.
• This compensatory mechanism allowed for CDK2 re-activation in the presence of CDK2 inhibitors, indicating drug adaptation.

Conclusions:

• CDK2 inhibition alone is insufficient to suppress cancer cell proliferation due to compensatory CDK4/6 activity.
• Combined inhibition of CDK2 and CDK4/6 may be necessary to overcome adaptation and enhance the efficacy of CDK2 inhibitors in clinical development.
• These findings highlight CDK plasticity and inform strategies for next-generation cancer therapies targeting cell-cycle kinases.